Anti-metastatic efficacy and safety of MMI-166, a selective matrix metalloproteinase inhibitor

Clinical and Experimental Metastasis

Volumn 18, Issue 1, 2000, Pages 61-66

  Maekawa, R ^a   Maki, H ^a   Wada, T ^a   Yoshida, H ^a   Nishida Nishimoto, K ^a   Okamoto, H ^a   Matsumoto, Y ^a   Tsuzuki, H ^a   Yoshioka, T ^a  

^a SHIONOGI AND CO LTD   (Japan)

Author keywords

Anti metastatic efficacy; MMP; MMP inhibitor; Safety

Indexed keywords

GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MMI 166; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; ENZYME ACTIVITY; FEMALE; LEWIS CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; TUMOR GROWTH; WEIGHT REDUCTION;

ANIMALS; ENZYME INHIBITORS; HUMANS; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM METASTASIS; SULFONAMIDES; TUMOR CELLS, CULTURED;

EID: 0035133606     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026553414492     Document Type: Article

References (45)

1. Matrix metalloproteinases: Novel targets for directed cancer therapy
2. Metalloproteinases and cancer invasion
3. Biology and biochemistry of proteinases in tumor invasiveness
4. Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression
5. Molecular and cellular basis of cancer invasion and metastasis: Implications for treatment
6. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis
7. Regulation of matrix metalloproteinases during extracellular matrix turnover
8. Matrix metalloproteinases and malignant disease: Recent development
9. Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue
10. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small cell lung carcinoma
11. Elevated levels of Mw 92,000 collagenase in human brain tumors
12. Expression and in situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer
13. Matrix metalloproteinase 2 (MMP-2) and matrix metalloproteinase 9 (MMP,-9) type-IV collagenases in colorectal cancer
14. Matrix metalloproteinase inhibitors: A new class of anti-cancer agent
15. Recent advances in matrix metalloproteinase inhibitor research
16. Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer
17. Matrix metalloproteinase inhibitors: Present achievements and future prospects
18. Emerging therapeutic advances for the development of second generation matrix metallo-proteinase inhibitors
19. Matrix metalloproteinase inhibitors as a novel anticancer strategy: A review with special focus on Batimastat and Marimastat
20. Recent advances in inhibitors of matrix metalloproteinases for cancer therapy
21. Clinical potential of matrix metalloprotease inhibitors
22. Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMI-2): N-sulfonylamino acid derivatives
23. Correlation of antiangio-genesis and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metallo-proteinase inhibitor
24. The purification of tissue inhibitor of metalloproteinase-2 from its 72 kDa progelatinase complex
25. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay
26. The growth of mouse bone marrow cells in vitro
27. Some statistical methods useful in circulation research
28. New tables for multiple comparisons with a control
29. Asymptotocally efficient rank invariant procedures
30. Synergy of the combination of nedaplatin with etoposide in murine and human lung carcinoma
31. Inhibition by human re-combinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16-F10 melanoma cells
32. Suppression of invasion by inducible expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in B16-F10 melanoma cells
33. Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells
34. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts
35. Inhibition of growth of human tumor cells in nude mice by a metalloproteinase inhibitor
36. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor
37. Matrix metalloprotenase inhibitor BB-94 (Batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice
38. Inhibition of organ invasion by the matrix metalloproteinase inhibitor Batimastat (BB-94) in two human colon carcinoma metastasis models
39. Effect of matrix metalloproteinase inhibitors on tumor growth and spontaneous metastasis
40. Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases
41. Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor
42. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice
43. Experimental metastasis is suppressed in MMP-9 deficient mice